US OptionsDetailed Quotes
TSHA240719P2500
- 0.35
- +0.10+40.00%
15min DelayClose Jul 19 15:59 ET
0.35High0.35Low
0.35Open0.25Pre Close2 Volume46 Open Interest2.50Strike Price70.00Turnover0.00%IV-0.47%PremiumJul 19, 2024Expiry Date0.36Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma6.11Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Taysha Gene Therapies Stock Discussion
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies (Nasdaq: TSHA) has announced a public offering of up to $75 million in common stock and pre-funded warrants. This offering allows certain investors the option to purchase pre-funded warrants instead of common stock. Additionally, underwriters Jefferies, Goldman Sachs, and Cantor have a 30-day option to buy up to 15% more shares under the same...
3 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
Company to host webcast on Tuesday, June 18, 2024, at 8:00 AM Eastern Time
Oral presentation by Elsa Rossignol, M.D., FRCP, FAAP, Principal Investigator of the REVEAL adolescent and adult trial at CHU Sainte-Justine and Colleen Buhrf...
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (Rmat) Designation Granted by U.S. FDA for Tsha-102 in Rett Syndrome
Benzinga· 47 mins ago
An investigational gene therapy, dubbed scAAV9/JeT-GAN, for a rare neurodegenerative disease, giant axonal neuropathy (GAN), that begins in early childhood was well tolerated and showed signs of therapeutic benefit in a Phase 1 trial led by the National Institutes of Health (NIH).
The study was suppo...
No comment yet